menu
    • menu

    Company profile for ILIAS Biologics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At ILIAS Biologics, we dedicate ourselves to the development of paradigm-shifting advances in human medicine. Exosomes, extracellular vesicles naturally released by cells, represent such an opportunity thanks to its unique ability to deliver biological information between cells. Our platform technology, EXPLOR™, makes it possible to load large therapeutic molecules into exosomes, and we are actively developing various therap...
    At ILIAS Biologics, we dedicate ourselves to the development of paradigm-shifting advances in human medicine. Exosomes, extracellular vesicles naturally released by cells, represent such an opportunity thanks to its unique ability to deliver biological information between cells. Our platform technology, EXPLOR™, makes it possible to load large therapeutic molecules into exosomes, and we are actively developing various therapeutic exosomes, Exo-Targets®, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ILIAS Biologicskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    40-20 Techno 6ro, Yuseong-gu, Daejeon 34014
    Telephone
    Telephone
    042-863-4450
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://iliasbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ilias-biologics-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    After $500M IPO, HK inno.N enters exosome drug delivery
    After $500M IPO, HK inno.N enters exosome drug delivery

    31 May 2022

    // Nick Paul Taylor FIERCEPHARMA

    https://www.fiercepharma.com/pharma/after-500m-ipo-hk-innon-enters-exosome-drug-delivery-ilias-pact

    Nick Paul Taylor FIERCEPHARMA
    31 May 2022
    Share Share
    ILIAS demonstrated the therapeutic effect of anti-inflammatory exosomes
    ILIAS demonstrated the therapeutic effect of anti-inflammatory exosomes

    28 Jun 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ilias-biologics-inc-demonstrated-the-therapeutic-effect-of-anti-inflammatory-exosomes-for-ischemia-reperfusion-induced-acute-kidney-injury-301320801.html

    PR NEWSWIRE
    28 Jun 2021
    Share Share
    ILIAS Biologics the 2nd POC study, showing anti-inflammatory of ILB202
    ILIAS Biologics the 2nd POC study, showing anti-inflammatory of ILB202

    02 Feb 2021

    // PRNASIA

    https://en.prnasia.com/releases/global/ilias-biologics-announces-the-2nd-poc-study-showing-anti-inflammatory-effects-of-ilb202-on-preterm-birth-307428.shtml

    PRNASIA
    02 Feb 2021
    Share Share
    ILIAS announces the 2nd POC study, showing anti-inflammatory effects of ILB202
    ILIAS announces the 2nd POC study, showing anti-inflammatory effects of ILB202

    01 Feb 2021

    // PRNASIA

    https://en.prnasia.com/releases/global/ilias-biologics-announces-the-2nd-poc-study-showing-anti-inflammatory-effects-of-ilb202-on-preterm-birth-307428.shtml

    PRNASIA
    01 Feb 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search